Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

2134P - Self-reported late effects, need for information and follow-up in long-term Hodgkin lymphoma survivors

Date

21 Oct 2023

Session

Poster session 07

Topics

Supportive Care and Symptom Management;  Survivorship

Tumour Site

Presenters

Lise Willumsen

Citation

Annals of Oncology (2023) 34 (suppl_2): S1080-S1134. 10.1016/S0923-7534(23)01268-1

Authors

L.H. Willumsen1, K.B. Smeland2, S.A. Eikeland2, A. Fossa2, H. Bersvendsen3, U. Fagerli4, R.S. Falk5, H.C. Lie6, C.E. Kiserud1

Author affiliations

  • 1 National Advisory Unit For Late Effects After Cancer Treatment, Departement Of Oncology, Oslo University Hospital - The Norwegian Radium Hospital, 0379 - Oslo/NO
  • 2 Oncology Department, Oslo University Hospital - The Norwegian Radium Hospital, 0379 - Oslo/NO
  • 3 Oncology Department, UiT The Arctic University of Norway, 9019 - Tromso/NO
  • 4 Oncology Department, NTNU - Norwegian University of Science and Technology - Faculty of Medicine and Health Sciences, 7006 - Trondheim/NO
  • 5 Oslo Center For Biostatistics And Epidemiology, Oslo University Hospital - Rikshospitalet, 0424 - Oslo/NO
  • 6 Department Of Behavioural Medicine, University of Oslo, 316 - Oslo/NO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2134P

Background

Hodgkin’s lymphoma survivors (HLSs) are at risk for late effects due to their early age at diagnosis, multimodal therapy and long life expectancy. Among HLSs, we explored self-reported late effects, and assessed their information needs regarding lifestyle (diet and physical activity) and rehabilitation, in addition to need for long-term follow-up and factors associated with these needs.

Methods

HLSs treated 1997-2006 and aged 18-49 years at diagnosis were identified by the Norwegian Cancer Registry and invited to participate in this population-based, cross-sectional study consisting of a questionnaire, blood tests, clinical examination and echocardiography. Information regarding histology, stage and treatment was retrieved from medical records. Descriptive statistics and logistic regression models were used.

Results

Among the participants (n=304, 59% response rate), median age at diagnosis was 29 years (range 8-49), median age at survey 45 years (21-70), median observation time 16 years (10-22) and 48 % were females. Ninety percent had classical HL, 62% had stage I-IIA disease, 94% received chemotherapy and 77% radiotherapy. Seventy-four percent reported to have experienced ≥1 late effects; concentration/memory problems (29%), numbness/nerve pain (32%) and dental problems (27%) were the most common. Forty-one percent reported chronic fatigue (CF). One third reported to have received follow-up for late effects. A total of 64% wanted information about lifestyle and/or rehabilitation, and 58% wanted regularly follow-up for late effects. In the multivariable models, CF (OR 2.2, 95%CI 1.2-4.1), short education (2.2, 1.2-4.0), being physical inactive (2.0, 1.1-3.5) were associated with increased likelihood of need for information about lifestyle and/or rehabilitation. CF was associated with increased likelihood of need for follow-up for late effects (2.1, 1.3-3.6).

Conclusions

HLSs report a high level of late effects and only a small proportion receive follow-up for these problems. Chronic fatigue is associated with need for information and follow-up, indicating that these patients could benefit from a more structured model for long-term follow-up than what is currently available.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.

Funding

Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426; Norwegian Extra Foundation for Health and Rehabilitation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.